How it works.

MRD Monitoring in Multiple Myeloma Made Easy.

What it is exactly.

EasyM™ is a non-invasive and highly sensitive, mass spectrometry-based M-protein monitoring test for patients with Multiple Myeloma (MM). EasyM™ identifies the patient’s unique M-protein peptide sequence (a biomarker for MM) and follows this unique sequence to quantify the change in M-protein levels over time.

Applied on peripheral blood, the test can be performed as frequently as needed, providing patients with a more convenient, non-invasive alternative for routine MRD monitoring throughout their treatment journey.

EasyM is a truly personalized, precise monitoring test for patients with Multiple Myeloma (MM) that is non-invasive and highly sensitive. It relies on sequencing the patients’ unique M-protein (a biomarker for MM), and then quantifying the change in M-protein levels over time. It is sensitive enough to detect Multiple Myeloma relapse 10 months earlier than traditional tests. Applied on peripheral blood, the test can be readily performed as frequently as needed providing each patient with better routine monitoring than available conventional testing.

See how EasyM™ Works

Higher Sensitivity

EasyM™ was able to detect and quantify M-protein in 79% of samples that were MRD-negative by NGS at 10^–5 cells.*¹

100% Patient Specificity

EasyM™ identifies and tracks the M-protein peptide sequence unique to each patient.

This allows EasyM™ to accurately monitor the patient’s M-protein even while being treated by the latest antibody therapeutics.

Non-Invasive Testing in Peripheral Blood

Patients do not require bone marrow aspirations for EasyM™.

With as little as 0.5 mL of serum, EasyM™ is able to monitor the disease status as frequently as required with greater convenience and comfort.

*Preliminary results based on interim data, are subject to change.

EasyM™ vs Comparable Methods.

Parameter / Method	EasyM	SPEP	IFE	NGS based
Analytical Sensitivity	⭐⭐⭐⭐⭐	⭐	⭐⭐	⭐⭐⭐⭐
Patient Specificity	⭐⭐⭐⭐⭐	⭐⭐⭐	⭐⭐⭐	⭐⭐⭐⭐⭐
Non-Invasive	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐
Early Relapse Detection	⭐⭐⭐⭐⭐	⭐	⭐	⭐⭐⭐⭐

Explore our recent publications

I’m a Clinician.

Discover the advantages of EasyM™ mass spectrometry-based blood test for MRD monitoring in multiple myeloma

Learn how we can collaborate along the journey to bringing a Multiple Myeloma blood test to your patients.

For clinicians

I’m a Patient.

Explore our vision to bring convenient, blood-based MRD monitoring to patients living with multiple myeloma.

Explore our vision for Multiple Myeloma blood tests, follow our progress and see how you can advocate for your needs.

for patients

I’m from Industry.

Consider including EasyM™ for improved disease monitoring in upcoming clinical trials for multiple myeloma therapies.

Learn how EasyM can be used for MM monitoring in a clinical trial for your therapy.

For Industry

Upcoming Conferences.

Sign up to follow our progress with bringing EasyM™ to the Myeloma community.

References

1. Slade M, et al. Blood 2022; 140 (Supplement 1): 4376–4377.